ES2524309T3 - Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico médico - Google Patents
Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico médico Download PDFInfo
- Publication number
- ES2524309T3 ES2524309T3 ES11165586.6T ES11165586T ES2524309T3 ES 2524309 T3 ES2524309 T3 ES 2524309T3 ES 11165586 T ES11165586 T ES 11165586T ES 2524309 T3 ES2524309 T3 ES 2524309T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- fragments
- disease
- protaquicinin
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 43
- 239000002243 precursor Substances 0.000 title claims abstract description 25
- 102000003141 Tachykinin Human genes 0.000 title description 23
- 108060008037 tachykinin Proteins 0.000 title description 23
- 238000003745 diagnosis Methods 0.000 title description 7
- 108010091748 peptide A Proteins 0.000 claims abstract description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 210000001124 body fluid Anatomy 0.000 claims abstract description 30
- 239000010839 body fluid Substances 0.000 claims abstract description 30
- 206010040047 Sepsis Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 17
- 208000013223 septicemia Diseases 0.000 claims abstract description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 13
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 13
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 12
- 208000014674 injury Diseases 0.000 claims abstract description 12
- 201000009906 Meningitis Diseases 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 11
- 230000008733 trauma Effects 0.000 claims abstract description 11
- 206010019196 Head injury Diseases 0.000 claims abstract description 10
- 208000023637 Multiple injury Diseases 0.000 claims abstract description 10
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 10
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 9
- 208000014644 Brain disease Diseases 0.000 claims abstract description 8
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 7
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 50
- 210000002381 plasma Anatomy 0.000 description 42
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 32
- 101800003906 Substance P Proteins 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 101800000923 Neuropeptide K Proteins 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 101000612657 Homo sapiens Paraspeckle component 1 Proteins 0.000 description 11
- 102100040974 Paraspeckle component 1 Human genes 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 208000006011 Stroke Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108090000189 Neuropeptides Proteins 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000004221 Multiple Trauma Diseases 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010008088 Cerebral artery embolism Diseases 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000003797 Neuropeptides Human genes 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000035987 intoxication Effects 0.000 description 5
- 231100000566 intoxication Toxicity 0.000 description 5
- 201000010849 intracranial embolism Diseases 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 5
- 101001062098 Homo sapiens RNA-binding protein 14 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 102100029250 RNA-binding protein 14 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PLSDWRYNZIVQKX-BGKYVOMCSA-N (3S)-3-amino-4-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CNC=N4)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)N PLSDWRYNZIVQKX-BGKYVOMCSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000034657 Convalescence Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 241000239220 Limulus polyphemus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101100465903 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psp3 gene Proteins 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010073085 tachykinin neuropeptide gamma Proteins 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010539 Congenital megacolon Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- -1 FNT-alpha Proteins 0.000 description 2
- 208000001730 Familial dysautonomia Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000004592 Hirschsprung disease Diseases 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 201000001638 Riley-Day syndrome Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000019479 dysautonomia Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 208000018290 primary dysautonomia Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150064712 FNTA gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101000655187 Mus musculus Tachykinin-3 Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229920003366 poly(p-phenylene terephthalamide) Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007126 proinflammatory cytokine response Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
- G01N2410/06—Kallidins; Bradykinins; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04009284 | 2004-04-20 | ||
| EP04009284 | 2004-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2524309T3 true ES2524309T3 (es) | 2014-12-05 |
Family
ID=34924661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11165586.6T Expired - Lifetime ES2524309T3 (es) | 2004-04-20 | 2005-04-20 | Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico médico |
| ES05747755.6T Expired - Lifetime ES2471403T3 (es) | 2004-04-20 | 2005-04-20 | Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico m�dico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05747755.6T Expired - Lifetime ES2471403T3 (es) | 2004-04-20 | 2005-04-20 | Utilización de precursores de taquicininas y/o de sus fragmentos en diagnóstico m�dico |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7838245B2 (enExample) |
| EP (3) | EP2518510A1 (enExample) |
| JP (2) | JP5095391B2 (enExample) |
| ES (2) | ES2524309T3 (enExample) |
| WO (1) | WO2005103712A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005103712A2 (en) | 2004-04-20 | 2005-11-03 | Sphingotec Gmbh | Use of precursors of tachykinins and/or their fragments in medical diagnostic |
| JP2009092550A (ja) * | 2007-10-10 | 2009-04-30 | Japan Health Science Foundation | うつ病またはうつ状態の同定方法 |
| CA2878025C (en) | 2008-01-18 | 2018-12-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| KR20130041961A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액에서 질환 또는 상태의 특징을 검출하는 방법 |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| EP2643483A4 (en) * | 2010-11-26 | 2014-04-30 | Immunexpress Pty Ltd | DIAGNOSTIC AND / OR SCREENING APPROPRIATIONS AND USES THEREFOR |
| KR20150035818A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법 |
| JP2015522260A (ja) | 2012-06-15 | 2015-08-06 | ハリー スティリ， | 疾患または状態を検出する方法 |
| TR201901828T4 (tr) * | 2013-01-08 | 2019-03-21 | Sphingotec Gmbh | Bir kişide kanser olma veya kanser tanısı konma riskinin öngörüsü için bir usul. |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| JP6419794B2 (ja) * | 2013-10-01 | 2018-11-07 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 主要な心臓有害事象に罹患する危険性を予測する方法 |
| EP4428251A3 (en) | 2014-09-11 | 2024-12-18 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| EP4356139A1 (en) * | 2021-06-18 | 2024-04-24 | sphingotec GmbH | A method for predicting sepsis and septic shock |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613431D0 (en) * | 1986-06-03 | 1986-07-09 | Medical Res Council | Human tachykinins |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| JPH082798B2 (ja) * | 1991-12-13 | 1996-01-17 | 日本全薬工業株式会社 | 抗体を利用した新しいタイプの鎮痛薬 |
| KR100430960B1 (ko) * | 1995-05-11 | 2004-10-28 | 거번먼트오브더유나이티드스테이츠오브아메리카,애즈리프리젠티드바이더세크러트리오브디아미 | 매우약독화된재조합일본뇌염바이러스를생성하는감염성일본뇌염바이러스cDNA클론및이의백신 |
| WO1998004689A1 (en) * | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB9606736D0 (en) * | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
| CA2190679A1 (en) * | 1996-11-19 | 1998-05-19 | Christopher J. Paige | Lymphocyte tachykinin |
| US6372440B2 (en) * | 1999-03-10 | 2002-04-16 | Magnesium Diagnostics, Inc. | Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses |
| EP2100901A1 (en) * | 1999-05-17 | 2009-09-16 | ConjuChem Biotechnologies Inc. | Modified Insulin and conjugates thereof |
| CA2311201A1 (en) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
| AU1057001A (en) * | 1999-11-08 | 2001-06-06 | Suntory Limited | Novel physiologically active peptides and process for producing the same |
| US7235531B2 (en) * | 1999-12-21 | 2007-06-26 | Takeda Pharmaceutical Company | Tachykinin-like polypeptides and use thereof |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US7425217B2 (en) * | 2000-11-16 | 2008-09-16 | Maier Nathan C | System and method for inhibiting cellular proliferation with tachykinins |
| IL158397A0 (en) * | 2001-04-18 | 2004-05-12 | Genset Sa | Polypeptides, their preparation and their use |
| EP1385958A2 (en) * | 2001-05-01 | 2004-02-04 | Geneprot, Inc. | Human tachykinin-related splice variants and compositions thereof |
| AU2002326769A1 (en) * | 2001-08-24 | 2003-03-10 | Incyte Genomics, Inc. | Extracellular messengers |
| WO2003025547A1 (en) * | 2001-09-21 | 2003-03-27 | Biomedlab Corporation | Method and device for screening analytes using surface plasmon resonance |
| US20030114763A1 (en) * | 2001-12-13 | 2003-06-19 | Reddy Shankara B. | Fusion of computerized medical data |
| EP1554309A2 (en) * | 2002-10-03 | 2005-07-20 | McGILL UNIVERSITY | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics |
| WO2004076614A2 (de) * | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| WO2005043111A2 (en) * | 2003-07-14 | 2005-05-12 | Ciphergen Biosystems, Inc. | Serum biomarkers for sars |
| WO2005103712A2 (en) | 2004-04-20 | 2005-11-03 | Sphingotec Gmbh | Use of precursors of tachykinins and/or their fragments in medical diagnostic |
-
2005
- 2005-04-20 WO PCT/EP2005/004254 patent/WO2005103712A2/en not_active Ceased
- 2005-04-20 ES ES11165586.6T patent/ES2524309T3/es not_active Expired - Lifetime
- 2005-04-20 JP JP2007508840A patent/JP5095391B2/ja not_active Expired - Fee Related
- 2005-04-20 ES ES05747755.6T patent/ES2471403T3/es not_active Expired - Lifetime
- 2005-04-20 EP EP12164004A patent/EP2518510A1/en not_active Withdrawn
- 2005-04-20 EP EP05747755.6A patent/EP1740957B1/en not_active Expired - Lifetime
- 2005-04-20 EP EP11165586.6A patent/EP2369350B1/en not_active Expired - Lifetime
- 2005-04-20 US US11/568,146 patent/US7838245B2/en not_active Expired - Lifetime
-
2010
- 2010-11-04 US US12/939,390 patent/US9188591B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 JP JP2012055452A patent/JP5607094B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012112978A (ja) | 2012-06-14 |
| US20110275091A1 (en) | 2011-11-10 |
| EP2369350B1 (en) | 2014-08-20 |
| US7838245B2 (en) | 2010-11-23 |
| WO2005103712A2 (en) | 2005-11-03 |
| JP5607094B2 (ja) | 2014-10-15 |
| US20080260640A1 (en) | 2008-10-23 |
| JP2007533985A (ja) | 2007-11-22 |
| EP1740957B1 (en) | 2014-03-12 |
| EP2369350A2 (en) | 2011-09-28 |
| EP2518510A1 (en) | 2012-10-31 |
| JP5095391B2 (ja) | 2012-12-12 |
| EP1740957A2 (en) | 2007-01-10 |
| ES2471403T3 (es) | 2014-06-26 |
| WO2005103712A3 (en) | 2006-12-14 |
| US9188591B2 (en) | 2015-11-17 |
| EP2369350A3 (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5607094B2 (ja) | 医療診断におけるタキキニンの前駆体および／またはその断片の使用 | |
| ES2431288T3 (es) | Uso de precursores de encefalinas y/o sus fragmentos en diagnosis médica | |
| ES2357606T3 (es) | Anticuerpos contra conjugados de fosforilcolina. | |
| JP2020529473A (ja) | 活性型α−シヌクレインに結合する抗体 | |
| CN110003201A (zh) | 帕潘立酮半抗原 | |
| Lui et al. | Targeting the tumor vasculature with engineered cystine-knot miniproteins | |
| US11472844B2 (en) | Peptidomimetics, method of synthesis and uses thereof | |
| Wu et al. | Proteomic quantification of lysine acetylation and succinylation profile alterations in lung adenocarcinomas of non-smoking females | |
| Lv et al. | Microbial imidazole propionate affects glomerular filtration rate in patients with diabetic nephropathy through association with HSP90α | |
| US20110045508A1 (en) | Urinary CA125 Peptides as Biomarkers of Ovarian Cancer | |
| Ernst et al. | Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid | |
| JP5430573B2 (ja) | 抗バソヒビンモノクローナル抗体のセット | |
| JP7476796B2 (ja) | 哺乳動物の嗅粘膜または嗅粘液の検査方法 | |
| Šimetić et al. | Laboratory use of hepcidin in renal transplant recipients | |
| KR20210090863A (ko) | 교모종줄기세포 엑소좀 유래 펩타이드를 포함하는 교모세포종의 진단용 바이오마커 조성물 | |
| JP2025082445A (ja) | 活性型ｉｌ－１８検出キット、及び検査方法 | |
| EP2859349B1 (fr) | Procédé de détection et/ou de dosage de l'annexine a3 d'un mammifère dans le sang ou un de ses dérivés | |
| HK40065091A (en) | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients | |
| Gnanapavan | Putative Biomarkers of Neuro-restoration in the CNS | |
| JP2010085363A (ja) | 糖尿病性末梢血管障害の検査のための方法、組成物およびキット | |
| KR20120116414A (ko) | 지정 서열 중합체 조성물의 혈청 단백질기반 검출을 통한 지정 서열 중합체 조성물의 설계，생체이용률，및 효능을 개선시키는 방법 |